Browse by category

Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The British Medical Journal (BMJ). More weight loss is also generally accompanied by greater harms, including stomach and bowel symptoms, fatigue and loss of lean (muscle) mass, and improvements are not sustained after stopping treatment. Sever

The latest analysis from the STAMPEDE (Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently) trial shows that over...